Palvella Therapeutics PVLA Change in Accrued Liabilities
Change in Accrued Liabilities at other companies
Other financials
Where this comes from
Reported directly by Palvella Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.
The official record: Palvella Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Palvella Therapeutics's change in accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Palvella Therapeutics's change in accrued liabilities?
- Palvella Therapeutics (PVLA) reported change in accrued liabilities of -$900K in Q1 2026.
- How has Palvella Therapeutics's change in accrued liabilities changed year-over-year?
- Palvella Therapeutics's change in accrued liabilities increased by 69.1% year-over-year, from -$2.91M to -$900K.
- What is the long-term trend for Palvella Therapeutics's change in accrued liabilities?
- Over 2 years (2021 to 2023), Palvella Therapeutics's change in accrued liabilities has grown at a -65.5% compound annual growth rate (CAGR), from $9.88M to -$1.18M.
- What does change in accrued liabilities mean?
- Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.